Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amdipharm limited - zonisamide - epilettiji, parzjali - anti-epilettiċi, - zonegran hu indikat bħala:monoterapija fit-trattament ta 'aċċessjonijiet parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja, fil-adulti li jkunu għadhom kif ġew iddijanjostikati bl-epilessija;terapija aġġuntiva fit-trattament ta' aċċessjonijiet parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja, fil-adulti, l-adoloxxenti u t-tfal ta 'sitt snin u' l fuq.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic acid - xanthomatosis, cerebrotendinous; metabolism, inborn errors - terapija biljari u tal-fwied - aċidu chenodeoxycholic huwa indikat għall-kura ta ' l-iżbalji inborn ta ' l-aċidu bili primarja sintesi minħabba n-nuqqas hydroxylase sterol 27 (li jippreżentaw bħala cerebrotendinous xanthomatosis (ctx)) fl-trabi, tfal u adolexxenti ta ' età żmien xahar għal 18-il sena u adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - zonisamide - epilessija - anti-epilettiċi, - monoterapija fit-trattament ta 'aċċessjonijiet parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja, fil-adulti li jkunu għadhom kif ġew iddijanjostikati bl-epilessija;terapija aġġuntiva fit-trattament ta' aċċessjonijiet parzjali bi jew mingħajr ġeneralizzazzjoni sekondarja, fil-adulti, l-adoloxxenti u t-tfal ta ' 6 snin u aktar.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mitsubishi pharma europe ltd - colestilan - iperfosfatemja - drogi għat-trattament ta 'iperkalimja u iperfosfatemija - il-kura ta 'iperfosfatemija f'pazjenti adulti b'mard tal-kliewi kroniku stadju 5 li jirċievu emodijalisi jew dijalisi peritoneali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - irbesartan, hydrochlorothiazide - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. din id-doża fissa kombinata hija indikata f'pazjenti adulti li l-pressjoni tad-demm ma tkunx ikkontrollata adegwatament fuq irbesartan jew b ' hydrochlorothiazide waħidhom (ara sezzjoni 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - aġenti antineoplastiċi - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

celgene europe bv - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - aġenti antineoplastiċi - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - aġenti antineoplastiċi - azacitidine betapharm huwa indikat għall-kura ta 'pazjenti adulti li mhumiex eliġibbli għat-trapjanti ta'ċelloli staminali ematopojetiċi (hsct) bil -: intermedji-2 u ta' riskju sindromi majelodisplastiċi (mds) skond l-international pronostiċi scoring system (ipss),lewkimja majelomonoċitika kronika (cmml) b'10 % sa 29 % tal-mudullun tal-blasts mingħajr disturbi majeloproliferattivi,lewkimja majelojde akuta (aml) b'20 % sa 30 % blasts u multi-lineage-displażija, skond l-organizzazzjoni dinjija tas-saħħa (who) il-klassifikazzjoni,l-aml b ' > 30 % tal-mudullun tal-blasts skond il-klassifikazzjoni tal-who.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan ireland limited - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - aġenti antineoplastiċi - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - aġenti antineoplastiċi - azacitidine qbil huwa indikat għall-kura ta 'pazjenti adulti li mhumiex eliġibbli għat-trapjanti ta'ċelloli staminali ematopojetiċi (hsct) bil -: - intermedja-2 u ta' riskju sindromi majelodisplastiċi (mds) skond l-international pronostiċi scoring system (ipss),- lewkimja majelomonoċitika kronika (cmml) b'10-29 % tal-mudullun tal-blasts mingħajr majeloproliferattivi-disturb, il - lewċemija mjelojde akuta (aml) b'20-30 % blasts u multi-lineage-displażija, skond l-organizzazzjoni dinjija tas-saħħa (who) il-klassifikazzjoni, l - aml b ' >30% tal-mudullun tal-blasts skond il-klassifikazzjoni tal-who.